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Serotonin is an ancient molecular signal and a recognized neurotransmitter brainwide distributed with particular presence in
hippocampus. Almost all serotonin receptor subtypes are expressed in hippocampus, which implicates an intricate modulating
system, considering that they can be localized as autosynaptic, presynaptic, and postsynaptic receptors, even colocalized within
the same cell and being target of homo- and heterodimerization. Neurons and glia, including immune cells, integrate a functional
network that uses several serotonin receptors to regulate their roles in this particular part of the limbic system.
1.Serotonin
Serotonin (5-hydroxytryptamine; 5-HT), named by Rapport
et al. (1948) [1], is one of the ubiquitous molecules
acting as messengers, well known as a neurotransmitter
and neuromodulator. Serotonin (Figure 1) is mostly found
outside the central nervous system [2]; it was ﬁrst identiﬁed
in enterochromaﬃn cells and named as “enteramine” by
Vialli and Erspamer in 1937 and conﬁrmed to be the same
entity with the “clotted blood” vasoconstriction eﬀects in
1952 [3].
2.SerotoninasanAncientMolecularSignal
The serotonergic system is an ancient sensor of diverse
stimuli and molecular signaling in single-celled eukaryotes,
plants, and animals [4–6].
The regulated expression of genetic material in every cell
is very important and a “regulatory lesson” learned over the
years is that small metabolites are often regulatory signals to
control gene expression. For “expensive” biosynthesis, as the
required for the serotonin precursor tryptophan, common
pathways are found in organisms that take advantage of the
aromatic structures; tryptophan serves as the precursor not
only of serotonin (Figure 2), but also of very important
compounds as niacin in eukaryotes, indoleacetic acid in
plants, and indole in bacteria. Regulatory strategies could be
compatible with other metabolic goals as organisms evolved
capable of obtaining tryptophan by feeding, with speciﬁc
plasma membrane transporters [7, 8].
Beyond the heterotrophic theory of the very ﬁrst living
organisms [9], serotonin could be used as speciﬁc signal,
after direct relation with tryptophan synthesis was con-
trolled, and speciﬁc monoamine transporters that do not
need the missing carboxyl group of the aminoacids [7, 10]
were present; later, it acquired functions of “hormone” and
growthfactor,andserotoninactivityasneurotransmitterwas
achieved at last [4]. In prenervous stages, serotonin regulates
basic developmental processes from cleavage divisions after
fertilization (proliferator) to morphogenetic cell movements
during gastrulation (morphogen) in sea urchin [11]. Pres-
ence of serotonin and its metabolite 5-hydroxyindoleacetic
acid in unicellular ciliate Tetrahymena pyriformis [12]a n d
increasing RNA production in the 5-HT stimulated protozoa
[13] suggested an active biogenic amine system with relevant
functions; interaction with GTPases might represent some2 The Scientiﬁc World Journal
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Figure 1:Serotonin(5-HT).Modiﬁed imagefromNCBIPubChem
Substance Database CID 5202.
of the earlier functions of serotonin (and biogenic amines)
before it could be vesiculated and its exocytosis could be
regulated for metazoan serotonergic systems [14, 15].
3.Serotoninasa Regulatory
Molecule inAnimals
This happy hormone, as recalled by Dr. Barnes [16], plays a
modulatory role in almost every physiological function and
isinvolved inmanybiologicalprocesses[2,17];furthermore,
the three related metabolites, 5HT, tryptophan, and mela-
tonin, are important regulators of feed intake, reproduction,
immunity, neurological function, and antistress responses
[18].
Serotonin is involved in natural reward-related physiol-
ogy and behaviour, from feeding to sexual activity [19]w i t h
many actions correlated to the involved location (cellular-
tissue-organ concentration) and the diﬀerent signaling can
also be associated with its more than fourteen recep-
tor subtypes, regulating physiological processes through
diﬀerent, even opposing mechanisms; these indoleamine
eﬀects include also serotonylation and interaction with
GTPases [2, 14, 15]. Serotonin inﬂuences body temperature,
breathing rhythms (respiratory system), heart rate (cardio-
vascular function in general), eating and bowel motility
(gastrointestinal system), ejaculatory latency and bladder
control, muscle contraction/relaxation and locomotion,
sleep, arousal, pain and sensory perception, emotions, and
cognition [2, 5, 20] with a well-known signaling role in
immune cells [21].
4.Se r o t o nininC e ntralN e rv o usS yst e m
Serotonergic neurons, ﬁrst discovered in the brainstem by
Dahlstr¨ om and Fuxe in 1964 [22], release 5-HT throughout
theCNS[23,24]asexpectedafterthebrainserotonindiscov-
ery [25]. 5-HT cell bodies are mainly localized in the raphe
nucleiwiththeiraxonsinnervatingalmosteverybrainregion
[17]. The hippocampus is a principal target of serotonergic
aﬀerents along with all the limbic system [26]. The serotonin
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Figure 2: Serotonin metabolism. Tryptophan is the precursor for
serotonin synthesis, with diﬀerent enzymatic reactions in plant and
animals [6]; hydroxylation is the rate limiting step (enzyme medi-
ated by tryptophan hydroxylase in animals or tryptamine hydrox-
ylase in plants), while decarboxylation is a rapid conversion by
thearomaticaminoaciddecarboxylase(tryptophandecarboxylase).
The catabolic metabolite of serotonin is 5-hydroxyindoleacetic
acid, via 5-hydroxyindole acetaldehyde enzymatically converted by
themembrane-boundmitochondrialﬂavoproteinmonoaminooxi-
dase. Modiﬁed images from NCBI PubChem Substance Database.
projections to hippocampus stem in a topographic order
from the midbrain dorsal and median raphe nuclei [27–
29] .T h er a tv e n t r a lh i p p o c a m p u sr e c e i v em o d e r a t e l yd e n s e
projectionsfromthecaudaldorsalrapheandessentiallynone
from the rostral dorsal raphe, with ﬁne serotonergic axons
and small varicosities widely distributed throughout the
hippocampus. Furthermore, beaded serotonergic axons with
large, spherical varicosities are also found in hippocampus;
median raphe nucleus predominantly innervate the stratum
lacunosum moleculare of the CA1 and CA3 regions and the
dentate hilus [26, 28, 30, 31]. The density of serotonergic
axons is highest in CA3, lower in dentate gyrus and lowest
in CA1 [26, 30] .A l m o s ta l ls u b t y p e so fs e r o t o n i nr e c e p t o r s
are expressed in hippocampus during ontogeny, so the
regulation of the serotonergic system is more than complex
[32, 33].
5. Serotonin Receptors
Heterogeneity in serotonin receptors was established by
the late 1950s, with Gaddum and Picarelli [34] proposing
two tryptamine receptors in the guinea-pig ileum: M andThe Scientiﬁc World Journal 3
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Figure 3: Serotonin main signaling pathways. 5-HT or agonists/antagonists for each receptor (•) interact in the extracellular side and
the conformational changes of 5-HTRs modify the activity of speciﬁc intracellular enzymes, which in time modify other targets state to
provoke diﬀerent cellular responses [43]. G-protein βγ pathways are not represented in the ﬁgure. All of the serotonin receptor subtypes are
represented for a hippocampal pyramidal cell, as reported, but subpopulations of these neurons might diﬀerentially express 5-HT receptors.
AC, adenylate cyclase; PLC, phospholipase C. The 7TMD images of each subtype receptor are represented with the deﬁned number of exons
that code for the mature protein [44]; putative intron location in correspondent pre-mRNA is marked by a lightning symbol (), and
alternative splicing sites are marked with stars ().
D, blocked with morphine and dibenzyline, respectively;
binding to serotonin receptors was also studied with [3H]
5-HT and [3H] LSD [35, 36] and more than twenty
years later a new classiﬁcation was proposed by Peroutka
and Snyder (1979): 5-HT1 and 5-HT2 receptors based on
radioligand binding techniques ([3H] 5-HT, [3H] LSD and
[3H] spiroperidol) [37].
With the use of speciﬁc radiolabelled ligands, there was a
new classiﬁcation [38] proposing 5-HT3 receptors although
5-HT1-like receptors were still considered a heterogeneous
entity. Others tried to adjust the new information and
ﬁnally, with the advances in molecular biology, the serotonin
receptors were cloned, ﬁnding more than three subtypes.
The Serotonin Club Receptor Nomenclature Committee
(SCRNC), reporting directly to the IUPHAR Committee
for Receptor Nomenclature, described a new classiﬁcation
of 5-HT receptors [39]. This classiﬁcation was based in
diﬀerent operational (selective agonists, antagonists, and
ligand-binding aﬃnities), structural (molecular structure),
and transductional (intracellular transduction mechanisms)
criteria.
Serotonergic receptors (Figure 3) were grouped in seven
classes 5-HT1–7, all of them belonging to the G-protein-
coupled receptor (GPCR) superfamily [40], except 5-HT3
which is a ligand-gated ion channel that belongs to the nico-
tinic acetylcholine receptor superfamily: cystein-loop trans-
mitter gated superfamily which constitutes heteropentamers
[5, 41, 42]. Particularly, subindex for the diﬀerent receptors
were arranged and the former 5-HT1C was renamed as
5-HT2C, for its transductional properties and molecular
structure [39]. In the paper, subscript will be used for 5-HT
subtype receptors after SCRNC, and normal line of type for
previous ﬁndings in subtype receptor will be written.
6. Ion Channel Serotonin Receptor
The 5-HT3 receptor is a cation-selective ion channel which
activation evokes neuronal excitation and neurotransmitter
release. There are two well-recognized genes encoding A
and B subunits, but additional C, D, and E genes expand
the diversity to heterooligomer formation of the pentameric
channel [45]. The diﬀerent composition might reﬂect dis-
tinct pharmacology and relevance to their function repre-
senting each one a diﬀerent subtype of receptor. These sub-
unitscaninteractwithothermembersoftheCys-loopsuper-
family, regarding the previous “M”-type serotonin of Gad-
dum and Picarrelli classiﬁcation [46].
7. Metabotropic Serotonin Receptors
Theseventransmembranedomain(7TMD)serotoninrecep-
tors belong to the “type A” family of GPCR, rhodopsin-like
receptors, grouped by Fredricksson et al. (2003) in the amine4 The Scientiﬁc World Journal
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Figure 4: cAMP signaling pathways. Serotonin receptors 5-HT1 and 5-HT5 interact with αi/0 G-protein inhibiting the formation of cyclic
adenylate monophosphate (cAMP) by adenylate cyclase (AC), while 5-HT4,5 - H T 6,a n d5 - H T 7 activate AC by means of αS G-protein.
βγ subunits of G-protein may interact in other signaling pathways, for example, modulating GIRK or calcium voltage gated channels.
Representation of β-arrestin (β-arr) is made to indicate other signaling pathways. Traditional ligands to study diﬀerent subtype receptors are
written in the extracellular zone; note that 5-HT7 may bind the traditional ligand for 5-HT1A as well as LSD (5-HT2 ligand).
receptor cluster [47]. They display a heterogeneous phyloge-
netic pattern with 5-HT2 forming one group and 5-HT1B-1F
forming another group; the rest of 5-HT receptor subtypes
can be related with other biogenic amine receptors clusters.
In other classiﬁcation [48], 7TMD 5-HT receptors can be
grouped in type 1 family that contains GPCRs for small
ligands binding in a cavity formed by TM-III to TM VI [49].
The7TMDser ot oninr ec ept orsar ec oupledt odiﬀerentG
proteins. The 5-HT1 receptors couple to Gαi/Gαo proteins;
the 5-HT2 r e c e p t o r sc o u p l et oG αq proteins; the 5-HT4,5 -
HT6 and 5-HT7 receptors couple to Gαs proteins, and the 5-
HT5 receptors are related to Gαi/Gαo proteins [44].
Activation of Gαs coupled receptors (Figure 4)l e a d st o
the stimulation of adenylyl cyclases elevating cyclic AMP
(cAMP), which as a second messenger interacts with other
proteins including ion channels and activating the protein
kinase A (PKA). This phosphorylating enzyme also activates
cAMP-responsive transcription factors like CREB modify-
ing gene expression. The interaction with other exchange
proteins directly activated by cAMP leads to alternative sig-
naling cascades besides the classical PKA. The interaction
with Gαi leads to inhibition of adenylyl cyclases, decreasing
production of cAMP [5].
The activation of Gαq/11 coupled receptors (Figure 5)
lead to the hydrolysis of membrane phosphoinositides
resulting in the formation of diacyl glycerol (DAG) and
inositol phosphates (IP3). IP3 can interact with the calcium
reservoirs,elevatingintracellularlevelsandactivatingprotein
kinase C [5, 50]. Serotonin receptors may also be coupled to
Gα12/13,mediating structuralchangeswithinthecellthrough
activation of the Rho signaling pathway [41].
The Gβγ dimeric subunit can interact with a variety of
enzymatic eﬀectors within the cell, like their action on gated
ion channels, regulation of particular isoforms of adenylyl
cyclase and phospholipase C, and phosphoinositide-3-kinase
isoforms (and ERK signaling) [51].
If so many receptor subtypes of serotonin make it
complex to understand, plethora of activities can be found
with the coupling to multiple G-proteins. There are diﬀerent
parameters in the activation pathway of the GPCR receptors,
considering multiple states instead of the traditional two-
state model of activation and forming dimers that may have
distinct pharmacology with respect to activation, signaling,
and internalization and the organization in microdomains at
the membrane level that may aﬀect coupling and traﬃcking
of G-proteins [52].The Scientiﬁc World Journal 5
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the extracellular signal-regulated kinases 1 and 2 (ERK1/2) [50]. Phospholipase A2 is eventually activated producing arachidonic acid (AA)
from phosphatidylcholine (PC), or phosphatidic acid (PA) by means of phospholipase D (PLD) [44, 50]. SERT is included in the diagram,
coexisting in astrocytes for example, to emphasize the intracellular participation of serotonin itself [14]. Other pathways including (Rho-
GEF) and (PI3K) are shown [51]. MEK, mitogen-activated protein kinase; PH, phosphohydrolase enzyme; PKA, protein kinase A-relation
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Promiscuous coupling of GPCRs to G-proteins is not a
surprise, and they can also signal without coupling to them;
they can activate a variety of cascades by arrestin-ergic
signalling, beside the original function of these proteins in
terminating coupling and endocytosis [53, 54].
In brief, there are thirteen genes coding for GPCR
serotonin receptors that may couple almost every G-protein
in the cell membrane and probably act without coupling to
them, and two recognized genes coding for the subunits of
cation-selective 5-HT3 ligand-gated ion channel pentameric
receptor.
This diversity is further complexed by the posttrans-
lational and co/posttransductional modiﬁcations of the
protein to be produced, without talking about oligomer-
ization of the serotonin receptors and single-nucleotide
polymorphisms. There are examples of this modiﬁcations in
the diﬀerent receptor families with alternative splicing, RNA
editing, palmitoylation, glycosylation, phosphorylation, and
proteolysis, to mention a few [55].
8. Serotonin Receptors
ExpressioninHippocampus
All the serotonin receptor families are remarkably expressed
in hippocampus, which is part of the limbic system, a
whole structure related with memory processing, emotional
association with memory, judgment, aﬀect, and motivation
or the organization of planned actions [26]. The innervation
of serotonergic pathways in hippocampus and the diverse
expression of serotonin receptors in this brain area reﬂect
the overall functions related to 5-HT, in particular with
cognition, mood and food intake. After recognition of hip-
pocampal serotonergic aﬀerents by histochemical methods
(ﬂuorescence, potassium dichromate), uptake of tritiated
serotonin was achieved corroborating the wide spread of
5-HT pathways [56]. Molecular biology of the speciﬁc
receptors for serotonin conﬁrmed this knowledge.
8.1. 5-HT1 Receptors. The hippocampus contains a high
density of 5-HT1 sites, most of which belong to the 5-HT1A
subtype [39]. Before classiﬁcation of serotonin receptors on
the basis of their molecular biology, distinction between
the receptors in this group was based on the aﬃnities
for 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
distinguishing 5-HT1A, lysergic acid diethylamide (LSD)
and mesulergine detecting 5-HT1C, later renamed as 5-
HT2C, and rauwolscine for 5-HT1D receptors, for example,
but ﬁndings of new receptors with aﬃnity for these ligands
may clarify error in quantitation of the former groups.6 The Scientiﬁc World Journal
8.2.5-HT1A. Farginetal.characterizedthegenomiccloneG-
21 that corresponded to 5-HT1A sequence [57]. Gozlan et al.
(1983)[58]hadpreviouslyreportedtheexistenceof5HT1—
like receptors in hippocampus on the basis of the bind-
ing experiments of [3H] 8-OH-DPAT. In 1986, Hoyer
et al. [59]a n dV e r g ´ e et al. [60] conﬁrmed these results
and compared binding of 5-HT1A and 5-HT1B; later char-
acterization was performed by chromatographic analyses
of the serotonin 5-HT1A receptor solubilized from the rat
hippocampus [61]. Activation of somatodendritic autore-
ceptorsdiminished5-HTsynaptictransmission[62]suggest-
ing that 5-HT1A might represent presynaptic receptors as
well as postsynaptic neurotransmission in hippocampus. At
cellular levels, 5-HT1A receptors are located postsynaptically
in pyramidal and granular neurons of the hippocampus
as well as extrasynaptic structures, by studies using highly
selective 5-HT1A antibodies that allowed conﬁrmation and
reﬁnement of autoradiographic results [41]. They function
as somatodendritic inhibitory receptors in raphe nuclei and
presynaptically in hippocampus [63]. 5-HT1A has also been
detected in some astrocytes, radial glia, and ependymal and
endothelial cells [64].
8.3. 5-HT1B. Molecular cloning of rat 5-HT1B receptor was
performed by Voigt et al. in 1991 [65]. Previously, 5-
HT1B was deﬁned as the nonspiperone sensitive [3H]5-
HT binding in brain [41]; localization of 5-HT1B was
describedwithlowdensitiesinhippocampus(gyrusdentatus
> CA1 ≥ CA3)b ya ﬃnity diﬀerences with [3H] 8-OH-DPAT
[60] and binding studies with [125I]iodocyanopindolol [66].
Immunohistochemistry analysis had also shown coexpres-
sion of 5-HT1B in hippocampal cells with other serotonin
receptors [67]. 5-HT1B receptors are responsible for the
presynaptic inhibition of neurotransmission at the local
synapses between axon collaterals of CA1 pyramidal cells
and other CA1 pyramidal neurons and interneurons [68].
Projectionneuronsfromhippocampusreachthebednucleus
of the stria terminalis, where presynaptic 5-HT1B receptors
are involved in the inhibition of glutamate transmission
[69]. Furthermore, 5-HT1B hippocampal GABAergic axon
terminal heteroreceptors inhibit neurotransmitter release
[70].
8.4. 5-HT1D. Hamblin and Metcalf in 1991 [71]d e s c r i b e d
sequence of human 5-HT1D serotonin receptor and two
genes known as 5-HT1Da and 5-HT1Db were reported [72].
It was clear later that 5-HT1Db was the homologue receptor
of rat 5-HT1B, so called 5-HT1B. Operational proﬁles
between the former 5-HT1Da and 5-HT1Db receptors
were almost indistinguishable, and similarities are still very
present [41]. 5-HT1Da remained as the homologue of
rat 5-HT1D, and so-called 5-HT1D. 5-HT1D binding sites
resemble those of 5-HT1B receptors in hippocampus with
very low presence [41, 73]. 5-HT1B/1D receptors are found
at pre- and postsynaptic sites but presynaptic receptors
are predominantly located on 5-HT hippocampal nerve
terminals [63].
8.5. 5-HT1E. There is not a clear characterization of 5-HT1E
due to the lack of speciﬁc ligands that might diﬀerentiate
this receptorsubtype;furthermore,expressionof 5-HT1E has
not been found in rodents, because there is a stop codon in
t h ec o r r e s p o n d e n tm R N A[ 41]. Cloning of this receptor was
achieved using cDNA synthesized from monkey cortex and
human hippocampal cDNA library [74] though conﬁrming
its presence in hippocampus, previously reported by the
existence of a 5-HT1E subtype in human brain with ﬁndings
in radioligand studies [75].
8.6.5-HT1F. When5-HT1F wasfound[76],itwasdesignated
as 5-HT1Eb due to its related pharmacological proﬁle; 5-
HT1F-labeling was moderate in granule cells of the dentate
gyrus and hippocampal pyramidal cells in CA1–CA3, con-
ﬁrming its expression in hippocampus [77].
8.7. 5-HT2 Receptors. Receptors from this group were orig-
inally recognized by ligands like ketanserin, mesulergine,
LSD, and spiperone, which were reported to have high
aﬃnities for 5-HT2 receptors compared to 5-HT1 group
[78]. These receptors are coupled to phosphatidylinositol
hydrolysis although some eﬀects may involve intracellular
calcium release via an independent mechanism [79]. Hoyer
et al. [80] used Ketanserin binding though localizing 5-HT2
receptors recognition sites in hippocampus.
8.8. 5-HT2A. On the basis of the similarity in exerting the
cellular eﬀects which reﬂected the structural relationship
with the former 5-HT1C receptor, Pritchett et al. (1988)
used oligonucleotides encoding this serotonin receptor and
found 5-HT2A sequence [81]. Julius et al. (1990) also found
an encoding sequence for 5-HT2 which was expressed in
hippocampus in a 10-fold lower level than in rat cortex
[82]. The 5-HT2A receptor refers to the classical D receptor
described by Gaddum and Picarelli in 1957 and deﬁned later
as 5-HT2 by Peroutka and Snyder in 1979 [37]. 5-HT2A
expression in human hippocampus was conﬁrmed with RT-
PCR technique [83]. Immunoreactivity for 5-HT2A receptor
in hippocampus was found primarily in the pyramidal cell
layer of CA1–CA3 and in the granular layer of dentate gyrus
[84]. Agonist studies with 1-(2,5-dimethoxy-4-iodophenyl)-
2-aminopropane (DOI) indicate postsynaptic receptors for
5-HT2A [63]; in prelimbic prefrontal cortex, most 5-HT2A
receptors were postsynaptically located, but presynaptic
axons and varicosities locations were found [85]. Cellular
localizationof5-HT2A receptorsinastrocyteshasbeenfound
in hippocampus [86].
8.9. 5-HT2B. The “last” 5-HT2-like receptor subtype to be
cloned was 5-HT2B [87] from rat stomach fundus. The
origin and comparable sequence to 5-HT1C/2 led them to
designate it as 5-HT2F (for fundus) and renamed as 5-HT2B
after consensus of SCRNC in 1994. Cloned human 5-HT2B
receptors had a high degree of homology with mouse and
rat receptors although with higher aﬃnity for ketanserin
and a lower aﬃnity for yohimbine; it was found at very
low presence in the whole brain [88]. Expression of 5-
HT2B receptors in cultured astrocytes from hippocampus
with Ca2+ increases after stimulation with alpha-methyl 5-
HT has been reported [89]. The presence of this receptor
in astrocytes was veriﬁed with immunohistochemistry andThe Scientiﬁc World Journal 7
westernblot analysis. Furthermore, microglial cell cultures
expresses 5-HT2B receptors, and they are involved in the
regulation of inﬂammatory cytokine production from blood
cells [90].
8.10. 5-HT2C. L¨ ubbert and colleagues cloned in 1987 [91]
themouse5-HT1C-mRNA(actually5-HT2C)extractedfrom
choroid plexus tumors; Julius et al. (1988) characterized a
cDNA encoding this protein and conﬁrmed the receptor
expression in neurons of many regions of central nervous
system by in situ hybridization and RNA blot analysis [92].
It was ﬁrst identiﬁed in porcine choroid plexus on the
basis of its pharmacological properties [93] and localized
by autoradiographic mapping in rat [94] and human brain,
particularly in hippocampus [80].
The overall distribution of 5-HT2C receptor was reported
by several studies with mRNA in situ hybridization [95–98].
The speciﬁcity of radioligand binding ([3H] mesulergine)
was compared with in situ hybridization by Mengod et
al. (1990), ﬁnding high signal in the pyramidal layer of
the CA3 ﬁeld of rostral rodent hippocampal formation,
while intense hybridization was found in the strata oriens
and radiatum of the caudal CA1 area and in the ventral
subiculum [97]. Furthermore, Abramowski et al. (1995)
compared [3H] mesulergine binding with speciﬁc antibody-
binding in rat and human brain [99] ;C l e m e t te ta l .
(2000) also studied the presence of 5-HT2C protein with
immunohistochemistry and western blotting with abundant
expression in rat hippocampus [100].
8.11.5-HT3 Receptors. 5-HT3 receptorbelongstotheligand-
gated ion channel superfamily and corresponds to the M
receptor of Gaddum and Picarelli [41, 101]; ﬁve subunits
have been cloned although only 5-HT3A and 5-HT3B are
recognized for rodents [102–106]. The various subtypes of
5-HT3 may well-correspond to the pentameric heterodimer
assembled between all subunits and their splice variants,
and also with other members of the cys-loop superfamily,
like a4-nAChR nicotinic receptor [46, 107] although this
association has not been detected in porcine native 5-
HT3 brain receptors [108]. On the contrary, association
and coimmunoprecipitation of 5-HT3 and P2X2 ATP-gated
channels has been reported [109].
All subunits have been found mainly in human intestine
[110]. 5-HT3 mRNA was found in rat hippocampus primar-
ily on interneurons, mediating indirect inhibitory eﬀects on
pyramidal neuron populations [111]. On the contrary, 5-
HT3 was found in human hippocampus with predominant
immunoreactivityassociatedwithpyramidalneuronsinCA2
and CA3; transcripts were also identiﬁed so hippocampal
cells can produce 5-HT3A and 5-HT3B functionally isoforms
of this ion channel [112].
8.12. 5-HT4 Receptors. The 5-HT4 receptor was ﬁrst
described in the central nervous system [113] stimulating
adenylate cyclase; with some useful radioligands, it was
showed to be distributed in hippocampus. It was cloned
[114] and mRNA was localized in hippocampus by in situ
hybridization [115].
The 5-HT4 receptor gene is very complex and has
several possible splice variants; there are at least nine
receptor splice variants reported with a number of carboxy-
terminal variants but no diﬀerence in aﬃnity for agonists
or antagonists [41]. There is evidence that suggests that
5-HT4 receptor activity enhances cognition and provides
neuroprotection, particularly on hippocampal eﬀects [116];
5-HT4 receptors on hippocampal cholinergic axon terminals
are neurotransmitter release facilitating [70].
8.13. 5-HT5 Receptors. The 5-HT5 receptor group consists
of two members: 5-HT5A and 5-HT5B; human 5-HT5B has
beendescribed,butitfailstoencodeafunctionalproteindue
to the presence of stop codons in the sequence [117–119].
Theystilllackphysiologicalcorrelation,inpartforthelackof
selective agonists; the transductions pathways have not been
well established although negatively coupling to adenylate
cyclase has been reported [41, 43, 120].
8.14. 5-HT5A. Cloning and distribution of 5-HT5A receptor
has been reported, ﬁnding high concentration in hip-
pocampus [119, 121, 122]. Although this receptor is a
well-recognized GPCR protein, the negatively coupling to
adenylated cyclase is not well established [120, 123–125],
andfurthermore,itscouplingtomultiplesignaltransduction
pathways has been reported [126]. The 5-HT5A receptor
is expressed predominantly by astrocytes with very weak
neuronal immunoreactivity [120].
8.15. 5-HT5B. Cloning and distribution of 5-HT5B receptor
has been reported as well, ﬁnding this receptor in hippocam-
pus [119, 127]. The levels of expression of 5-HT5B mRNA
in hippocampus were high, with predominant expression
in CA1 pyramidal cells [128]. It is a pseudogene in man
[129], and it has been proposed that the upregulation found
(particularly in hippocampus) for mice 5-HT5B receptor, in
response of social isolation stress, might be undertaken in
humans by another receptor like 5-HT5A [130].
8.16. 5-HT6 Receptors. Ruat et al. (1993) cloned 5-HT6
receptor [131], starting from the sequence of rat histamine
H2 receptor with two transcripts evidenced. mRNA was
detected in hippocampus and in transfected COS-7 cells 5-
HT6 receptor was positively coupled to adenylate cyclase.
Hybridization signal of 5-HT6 mRNA was detected in CA1,
CA2, and CA3 ﬁelds of hippocampus as well as in dentate
gyrus [128].
8.17. 5-HT7 Receptors. Ruat et al. (1993) also cloned the
putative 5-HT7 receptor and localized it at hippocampus
[132]. It is diﬀerentially expressed in CA1 cells preferentially
localized on the cell body but absent in interneurons
[133]. The expression in the limbic areas suggests that
these receptors mediate serotoninergic controls in functions
like mood, learning, or neuroendocrine and vegetative
behaviors. The emerging functions of hippocampus involve
several neurotransmitter networks, where 5-HT7 receptors
can be functioning. AMPA receptor-mediated transmission
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postsynaptically by 5-HT7, while 5-HT1A receptors inhibit
this transmission both pre- and postsynaptically [134].
9. Serotonergic ModulationinHippocampus
Among the various major neurotransmitter signaling, like
monoaminergic, glutamatergic, and nitrergic neurotrans-
mitter systems that might be involved in some plastic
modiﬁcations of hippocampus particularly after stress expo-
sure [135], serotonergic system is very interesting for its
complexity and regulation.
Almost all pre- and postsynaptic serotonin receptors
havebeenidentiﬁedinhippocampus;furthermore,the5-HT
transporter (SERT, 5-HTT) plays a key role in serotonergic
neurotransmission, and it is condition-regulated in hip-
pocampus [136, 137]. In addition, tryptophan hydroxylase
(TPH), the rate-limiting enzyme for producing serotonin,
plays another key role in the regulation of this system; TPH1
andTPH2havebeenfoundinhippocampus[138].Theother
key enzyme in serotonergic system is monoamine oxidase
A, responsible for 5-HT degradation [139], expressed in
hippocampus as well.
Regulationofserotoninsystemisveryimportantanddis-
turbances in this matter are related to anatomical, functional
and behavioural anomalies, including neurologic and psy-
chiatric disorders as obsessive-compulsive disorder, bulimia,
chronic impulsivity, obesity and drug addiction, aggression,
-major- depression, suicide, anxiety, schizophrenia, mania,
autism, Alzheimer’s disease and also sudden infant death
syndrome [43, 139–142].
The function of serotonin as neurotransmitter seems to
bedevelopedatlastinevolution,andionotropicchannelsare
related to rapid neuronal activation, particularly in enteric
nervous system [4]. Serotonin, as metabotropic eﬀector,
has been recognized as a trophic factor, particularly during
development including morphogenetic activities as cell pro-
liferation, migration and diﬀerentiation [137, 143]; during
adulthood, depletion in serotonin decreases neurogenesis in
the dentate gyrus [144] though 5-HT plays a critical role in
the neuronal organization of the hippocampus [145].
Several metabotropic eﬀects of serotonin have been
related to brain-derived neurotrophic factor (BDNF) expres-
sion [144] and BDNF itself promotes the development and
function of serotonergic neurons [140]. This kind of interac-
tionbetweenneurotrophicfactorsandneurotransmittershas
been reported also with steroids; the regulation of HPA axis
by serotonin and vice versa is well documented [146, 147];
sexual steroids have this intricate correlation as well [148].
Thekeyforunderstandingtheserelationshipsistheexistence
of multiple receptors and ligand interaction for molecular
signaling.
On the other hand, hippocampus-dependent memory
formation uses long-term potentiation (LTP) as a pivotal
role. Cross-talk between the cAMP signal transduction
system and LTP has been reported, with a critical linkage
between Ca2+ and cAMP signaling [149]. At this level, all
of the serotonin receptors seem to be directly involved in
the normal function of hippocampus in mood regulation
and memory formation; neurogenesis is thought to be one
of the involved processes for long lasting changes related to
hippocampal function, particularly because dentate gyrus is
oneoftheprominentareasofadultbrainneurogenesis[150].
The 5-HT1A is the most likely involved receptor in
regulation of neurogenesis in the dentate gyrus [150]; it is
expressed on raphe serotonin neurons as an autoreceptor
[151], acting as a negative regulator of neuronal activity in
presynaptic locations in hippocampus, with very important
function in the balance of serotonin reservoirs. 5-HT1A also
inhibits neuronal ﬁring, activating G-protein-gated inwardly
rectifying potassium (GIRK) currents and inhibiting Ca2+
channels [44]; it is involved in the inhibition of long-term
potentiation (LTP) by the inhibition of NMDA function
[152].
As one of the most “important” members of serotonin
receptors, 5-HT1A receptor is the best characterized and
its ligands are used extensively. The mutant (knockout)
mice lacking this receptor exhibits enhanced anxiety-related
behaviour [153, 154]. The “speciﬁc” 5-HT1A ligand 8-OH-
DPAT has been used to establish the roles of this receptor
as trophic factor and in neurotransmission as well, but 5-
HTT (SERT) recognizes this ligand and likewise modulates
anxiety-related behaviour [136, 155].
The therapeutic eﬀects of serotonin-selective reuptake
inhibitors (SSRI), “speciﬁcally” acting on SERT function,
are well documented, and several theories are proposed to
explain the retarded actions in successfully treated patients
[156–158]. SSRIs are the most widely prescribed class
of antidepressants, which increases synaptic levels of 5-
HT in hours or days, but exerts the therapeutic response
several weeks later [159]. The increasing levels of 5-HT
cause a desensitization of 5-HT1A autoreceptors with a
lesser inhibition caused by this receptor in raphe neurons,
leading to a facilitation of 5-HT signaling [160]. There
is a diﬀerential response of SSRI’s desensitizing 5-HT1A
presynaptic or postsynaptic receptors; the speciﬁc serotonin
receptor antagonist WAY 100635 also promotes diﬀerential
changes in autoreceptors compared to postsynaptic 5-HT1A
receptors [160, 161].
SERT and 5-HT1A are the most studied therapeutic tar-
gets although several serotonin receptors are involved in hip-
pocampus activities, particularly 5-HT4, 5-HT6, and 5-HT7
that activate cAMP signaling increasing CREB, which may
increase the expression of BDNF [150]. Furthermore, 5-HT4
activation may cause a faster direct activation of 5-HT neu-
rons, increasing their ﬁring and causing desensitization of 5-
HT1A [159]. 5-HT2 receptors involve an alternative signaling
pathway to cAMP, where increasing Ca2+ levels is of par-
ticular importance, relying on the crosstalk between cAMP
signaling and Ca2+-regulated adenylyl cyclases. Knockout
phenotype for 5-HT2A shows decreased, anxiety while the
one for 5-HT2C shows increased appetite, overweight, and
cognitive impairment. Serotonin receptor 5-HT2C is proba-
bly the most important receptor related to food intake and
energy balance (satiety and obesity), with viable targeting for
weight control [20].
T h em o s tr e p r e s e n t a t i v en e u r o t r a n s m i t t e rr e c e p t o rf o r
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is also involved in LTP modulation in hippocampus [162].
The knockout phenotype for 5-HT3A has reduced pain
perception and variants of the 5-HT3A receptor have been
associated with bipolar disorder and schizophrenia [43].
Serotonergic neuronal-glial interactions (Figure 6)h a v e
been proposed to play a signiﬁcant role in the development
of several CNS pathologies [163]. Some serotonin receptors
aremainlyexpressedinglia.5-HT5A correlateswithastrocyte
maturity and activity, increasing its levels after induced
gliosis [120] although its expression in pyramidal cells of
hippocampus has been reported [117]. Addition of cAMP
analogues to astrocyte cultures decreases 5-HT1A expression
and increases 5-HT5A, therefore suggesting a direct neuronal
regulation of astrocyte homeostasis, as cAMP intracellular10 The Scientiﬁc World Journal
increases might activate and sensitize astrocytes to respond
at serotonin signaling from neurons that can supress gliosis
in vivo [120].
Each cell type can modify its serotonin receptor expres-
sion depending on the diﬀerentiation time and relationship
in a particular network. Mouillet-Richard et al. (2000) have
shownthediﬀerentiatingchangesthaninductedserotonergic
1C11∗5HT cells can exhibit [164], sequentially expressing
three diﬀerent serotonin receptor subtypes (5-HT1B/1D,5 -
HT2B, and 5-HT2A). Although cell cultures do not represent
reliable conditions of in vivo diﬀerentiation, they help us
understand how cells can adapt to changing media. The 5-
HT2 receptorsarereferredtoasprogrammablereceptorsthat
may not inﬂuence development although this process aﬀect
their number, aﬃnity, or function; the coupling eﬃciency
of the receptor may change in time, in correlation to a
developmental change of phosphatidylinositol hydrolysis-
second messenger system [165].
In conclusion, the speciﬁc changes that modulate sero-
tonin signaling can be performed by serotonin itself; the
levels of serotonin that can be reached in the synapses,
or as a volume transmission, is of outstanding importance
to understand the rate of change in the 5-HT signaling
itself, time of action might conduce to one response or the
contrary, considering that all the cell types in hippocampus
are involved in this modulation and function. Serotonin can
actdirectlyintoneuronandgliaafterSERTincorporation,an
ancient function for this biogenic amine and probably with
more importance during development.
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